



ევროკავშირი
საქართველოსთვის
Project funded by the European Union



EU programme “Support to Georgia’s Researchers’ Mobility”
&
EU ENI East Twinning project “Supporting inter-sectoral collaboration possibilities between
Research and Industry”

Selecting and advertising HEU Calls for Georgian Stakeholders



GRMP
Georgia's Researchers'
Mobility Programme



umweltbundesamt^U
ENVIRONMENT AGENCY AUSTRIA



**JOANNEUM
RESEARCH**

FWF
Der Wissenschaftsfonds.



DLR Projektträger

FFG
Promoting innovation.



This slides has been produced with the assistance of the European Union. Its contents are the sole responsibility of the project implementing partners and do not necessarily reflect the views of the European Union.

Step 1: Find the right HEU Calls

1. Published Working Programmes: <https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-search>

- + Several thematically sorted documents, covering one specific area of HE (e.g. Health, Widening...)
- + Information are available way in advance (eventually you can get even access to Draft WP's)
- No filter options available

2. Search Mask: <https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/how-to-participate/reference-documents>

- + Diverse filtering options
- + always up to date
- calls only visible when published
- no central document

3. Dedicated events/webinars: depending on host organisation

- + Calls are presented and explained
- + Possibility to ask questions
- only at a certain time


Funding and Tenders Portal (Search Mask)

Cookies

This site uses cookies to offer you a better browsing experience. Find out more on [how we use cookies and how you can change your settings](#).


I accept cookies

I refuse cookies

European Commission


Funding & tender opportunities

Single Electronic Data Interchange Area (SEDIA)

English 

Register

Login

SEARCH FUNDING & TENDERS

HOW TO PARTICIPATE


PROJECTS & RESULTS

WORK AS AN EXPERT

SUPPORT

Horizon Europe (HORIZON) clear filter


Type your Keywords...





☒ Match whole words only

☒ GRANTS ☐ TENDERS



Submission status

Forthcoming (1)




Open for submission (12)


Closed (8)

Programming period

2021 - 2027 (21)  

Funding and tenders (21)

 Need help?  

Sort by: Submission status 

Grant ERC ADVANCED GRANTS


Open for submission

Programme	Horizon Europe (HORIZON)	Deadline model	single-stage
ID	ERC-2021-ADG	Opening date	20 May 2021
Types of action	HORIZON ERC Grants	Deadline date	31 August 2021 17:00:00 Brussels time

Grant EIC Transition Open 2021

Open for submission

Programme	Horizon Europe (HORIZON)	Deadline model	single-stage
ID	HORIZON-EIC-2021-TRANSITIONOPEN-01	Opening date	19 May 2021



Call example

Grant

Enhancing synergies between the EIC and Startup Europe

Forthcoming

Programme	Horizon Europe (HORIZON)	Deadline model	single-stage
ID	HORIZON-EIC-2021-STARTUPEU-01-01	Opening date	01 June 2021
Types of action	HORIZON Coordination and Support Actions	Deadline date	22 September 2021 17:00:00 Brussels time

Deconstructing a call text

Topic ID

HORIZON-CL6-2021-BIODIV-01-11: What else is out there? Exploring the connection between biodiversity, ecosystems services, pandemics and epidemic risk

Specific
Conditions

Expected EU contribution per project: between EUR 4 and 6 Million

Indicative budget: Total budget for the topic is EUR 12 Mililion

Type of Action: Research and Innovation Action

Eligibility conditions: see Annex B

Technology Readiness Level: Activities are expected to archive TLR 3-5

Expected
Outcome

Successful proposal will contribute to European Green Deal priorities and the EU biodiversity strategy for 2030, whilst supporting the EU's response to the coronavirus and other zoonotic outbreaks, in the context of EU's goal of leading just digital, economic and ecological transitions that will leave no one behind, One Health approaches, and the future European Health Union. **Projects results** are expected to contribute to [...]

Scope

Wildlife microbiomes, whether symbiotic, commensal or pathogenic, and their potential to spread by crossing interspecies barriers, eventually reaching humans via transitional interfaces (e.g. peri-urban, farming areas), are still largely unknown. [...] The impacts of land use and climate change on biodiversity, ecosystem services and pandemics should be also taken into account, as well as any recent IPBES reports on the links between biodiversity and pandemics [...]

Deconstructing a call text

HORIZON-CL6-2021-CLIMATE-01-06 Resilient livestock farming systems under climate change

Specific conditions

Expected EU contribution per project

The EU estimates that an EU contribution of around EUR 12.00 million would allow these outcomes to be addressed appropriately. Nonetheless, this does not preclude submission and selection of a proposal requesting different amounts.

Indicative budget

The total indicative budget for the topic is EUR 12.00 million.

Type of Action

Research and Innovation Actions (RIA)

Deconstructing a call + example

- **Specific Conditions:** main information about the call
- **Expected Outcomes:** what is supposed to be achieved




Outcomes ... → Impact

- **Scope:** presents what exactly is expected to be done



Research Work to be done



Consortium

Work Consortium Impact Budget

HORIZON-HLTH-2022-DISEASE-06-03-two-stage: Vaccines 2.0 - developing the next generation of vaccines

Specific conditions	
<i>Expected EU contribution per project</i>	The Commission estimates that an EU contribution of around EUR 8.00 million would allow these outcomes to be addressed appropriately. Nonetheless, this does not preclude submission and selection of a proposal requesting different amounts.
<i>Indicative budget</i>	The total indicative budget for the topic is EUR 40.00 million.
<i>Type of Action</i>	Research and Innovation Actions

Expected Outcome: This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 3 “*Tackling diseases and reducing disease burden*”. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to all of the following expected outcomes:

- The scientific and clinical communities use the increased knowledge on pathogens and better understanding of the immune system’s role in infectious diseases to develop vaccines with improved efficacy.
- Vaccine manufacturers use more innovative and sustainable manufacturing technologies and improved GMP manufacturing know-how for producing the next generation of vaccines.
- A diversified portfolio of vaccine candidates ready for testing in clinical trials help policy makers and funders to make informed decisions about support to vaccine development.
- New innovative and improved design of preclinical/clinical studies that match the features of the next generation of vaccines is available for clinical community and regulators, and will shorten vaccine development time.

Scope: Infectious diseases, including antimicrobial resistant (AMR) infections, remain a major threat to health and health security in the EU and globally. The availability of more effective, accessible and affordable vaccines would provide the most cost-effective preventive measure against the health threat of epidemics and AMR pathogens. Vaccines against diseases, such as AIDS, tuberculosis (TB), malaria, neglected tropical diseases, hepatitis C and water-borne diseases are essential to achieve the WHO targets to control the spread of infectious diseases. The first generation of vaccines against some of the pathogens have proven to be suboptimal and not effective enough to protect the population. Many viruses of pandemic potential are variable in their surface antigen composition, and novel technologies are required to develop efficient vaccines against each new variant efficiently and in a short timeframe. To ensure that

more effective, accessible and affordable vaccines against all major infectious diseases become a reality, it is essential to sustain a diverse and modernised vaccine development pipeline.

Proposals should aim to diversify and accelerate the global vaccine research and development pipeline, and to strengthen the current leading role of the EU in vaccine research and development. Proposals should cover those pathogens, which still lack vaccines of sufficient efficacy, but where earlier efforts have already produced promising vaccine candidates.

The proposals should address several of the following areas:

- Innovation and integration of expertise and capabilities, including alignment of preclinical and clinical models, biomarker studies and new vaccine approaches from discovery to late stage development, from bench-based research to clinical development of promising preventive candidates.
- Application of iterative processes (including cross-learning, back-translation steps, integrative analysis of data) to allow exploitation and integration of novel findings between clinical, preclinical and discovery research and development.
- Deciphering mechanisms of protection of candidates, new approaches to antigen discovery and immunogen engineering, reverse vaccinology, evaluation of vaccines in novel platforms and technologies, novel adjuvants, innovative vaccine manufacturing approaches, relevant animal models, evaluation of alternative vaccine delivery routes.

Effective, evidence-based decision-making for progression of vaccine candidates in the pipeline based on transparent and objective portfolio management. Regulatory requirements be considered. Sex, gender, age and socio-economic factors should be taken into account.

HORIZON-HLTH-2022-DISEASE-06-03-two-stage: Vaccines 2.0 - developing the next generation of vaccines

Specific conditions	
<i>Expected EU contribution per project</i>	The Commission estimates that an EU contribution of around EUR 8.00 million would allow these outcomes to be addressed appropriately. Nonetheless, this does not preclude submission and selection of a proposal requesting different amounts.
<i>Indicative budget</i>	The total indicative budget for the topic is EUR 40.00 million
<i>Type of Action</i>	Research and Innovation Actions

Expected Outcome: This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 3 "Tackling diseases and reducing disease burden". To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to all of the following expected outcomes:

- The scientific and clinical communities use the increased knowledge on pathogens and better understanding of the immune system's role in infectious diseases to develop vaccines with improved efficacy.
- Vaccine manufacturers use more innovative and sustainable manufacturing technologies and improved GMP manufacturing know-how for producing the next generation of vaccines.
- A diversified portfolio of vaccine candidates ready for testing in clinical trials help policy makers and funders to make informed decisions about support to vaccine development.
- New innovative and improved design of preclinical/clinical studies that match the features of the next generation of vaccines is available for clinical community and regulators, and will shorten vaccine development time.

Scope: Infectious diseases, including antimicrobial resistant (AMR) infections, remain a major threat to health and health security in the EU and globally. The availability of more effective, accessible and affordable vaccines would provide the most cost-effective preventive measure against the health threat of epidemics and AMR pathogens. Vaccines against diseases, such as AIDS, tuberculosis (TB), malaria, neglected tropical diseases, hepatitis C and water-borne diseases are essential to achieve the WHO targets to control the spread of infectious diseases. The first generation of vaccines against some of the pathogens have proven to be suboptimal and not effective enough to protect the population. Many viruses of pandemic potential are variable in their surface antigen composition, and novel technologies are required to develop

efficient vaccines against each new variant efficiently and in a short timeframe. To ensure that more effective, accessible and affordable vaccines against all major infectious diseases become a reality, it is essential to sustain a diverse and modernised vaccine development pipeline.

Proposals should aim to diversify and accelerate the global vaccine research and development pipeline, and to strengthen the current leading role of the EU in vaccine research and development. Proposals should cover those pathogens, which still lack vaccines of sufficient efficacy, but where earlier efforts have already produced promising vaccine candidates.

The proposals should address several of the following areas:

- Innovation and integration of expertise and capabilities, including alignment of preclinical and clinical models, biomarker studies and new vaccine approaches from discovery to late stage development, from bench-based research to clinical development of promising preventive candidates.
 - Application of iterative processes (including cross-learning, back-translation steps, integrative analysis of data) to allow exploitation and integration of novel findings between clinical, preclinical and discovery research and development.
 - Deciphering mechanisms of protection of candidates, new approaches to antigen discovery and immunogen engineering, reverse vaccinology, evaluation of vaccines in novel platforms and technologies, novel adjuvants, innovative vaccine manufacturing approaches, relevant animal models, evaluation of alternative vaccine delivery routes.
- Effective, evidence-based decision-making for progression of vaccine candidates in the pipeline based on transparent and objective portfolio management. Regulatory requirements be considered. Sex, gender, age and socio-economic factors should be taken into account.

Group Work: Selecting and advertising HEU Calls for Georgian Stakeholders

- Research of relevant calls by using the respective working programmes and/or Search Tools (Funding & Tenders Portal)
 - Focus on your clients/target group
- Decode and select the “right” calls
- Develop mechanisms and strategies to present them to relevant stakeholders
 - the research and innovation community in Georgia
 - particular promising actors
- Refine and present selected calls to Georgian stakeholders in a targeted approach. Consider use of formats and media for each case!

Group Work: Core functions of NCP, current measures and opportunities for Georgia

Divide into groups, consisting of both NCPs + Grants office representatives, targeting the priority fields, identified by TWINNING:

1. ICT (IT services, interoperability, AI, cybersecurity)
2. Art & Humanities / Cultural Heritage
3. Food and Agriculture (Food quality and safety, future farming, and new technologies)
4. Renewable Energy (research capacity and infrastructure, green hydrogen, solar energy)
5. Innovative Health System (research support, bacteriophages and herbal medicine)
6. Circular Economy/Waste Management

Summarise and describe your results and present to the whole group (select 1 person to do so)



Horizon Europe structure



Pillar I

EXCELLENT SCIENCE

- European Research Council
- Marie Skłodowska-Curie
- Research Infrastructures



Pillar II

GLOBAL CHALLENGES & EUROPEAN INDUSTRIAL COMPETITIVENESS

6 Clusters

- Health
- Culture, Creativity & Inclusive Society
- Civil Security for Society
- Digital, Industry & Space
- Climate, Energy & Mobility
- Food, Bioeconomy, Natural Resources, Agriculture & Environment
- Joint Research Centre



Pillar III

INNOVATIVE EUROPE

- European Innovation Council
- European Innovation Ecosystems
- European Institute of Innovation & Technology

WIDENING PARTICIPATION AND STRENGTHENING THE EUROPEAN RESEARCH AREA

- Widening participation & spreading excellence
- Reforming & Enhancing the European R&I system




ევროკავშირი
საქართველოსთვის
Project funded by the European Union



[EU Twinning in Science-Business links](#)

[EU Georgia's Researchers' Mobility Programme](#)

მადლობა ყურადღებისთვის
Thank You!



European
Commission